Tegsedi (inotersen) has been approved in Brazil to treat stage 1 or 2 nerve…
Articles by Ana Pena, PhD
Although uncommon, eye manifestations can affect patients with familial amyloid polyneuropathy (FAP). These are mostly caused by opacities…
An affordable, portable, and non-invasive human motion tracking system based on an RGB-D camera can be useful for monitoring…
Autonomic symptoms are common among patients with hereditary ATTR amyloidosis, usually accompany the progression of peripheral neuropathy, and…
The case of a 17-year-old boy who experienced the first symptoms of familial amyloid polyneuropathy (FAP) before the…
Urinary and sexual problems are highly prevalent in people with familial amyloid polyneuropathy (FAP) and should be tackled…
Therapy with Vyndaqel (tafamidis) nearly stops or slows the progression of familial amyloid polyneuropathy (FAP) in most…
Variants in two genes involved in the body’s immune response and inflammation were associated with age-of-onset of symptoms in…
Tegsedi (inotersen) continues to slow progression of familial amyloid polyneuropathy…
Long-term treatment with Vyndaqel (tafamidis) is safe and well-tolerated by patients with…